Pfizer released positive Phase 2b data for PF-3944, their once-monthly GLP-1 obesity candidate acquired from Metsera. The company says it showed significant weight loss and a favorable safety profile. They plan to launch a large Phase 3 program in 2026. This pushes Pfizer into the obesity market with a less frequent dosing schedule than some competitors. The stock is trading around $26.78, slightly below the analyst consensus of $28.74. P/E is sitting at 19.7. One thing to watch is cash generation and dividend coverage as R&D spend likely increases for the new trials.